Literature DB >> 30978358

Progression of Celiac Disease in Children With Antibodies Against Tissue Transglutaminase and Normal Duodenal Architecture.

Renata Auricchio1, Roberta Mandile2, Maria Rosaria Del Vecchio2, Serena Scapaticci2, Martina Galatola2, Mariantonia Maglio2, Valentina Discepolo3, Erasmo Miele2, Donatella Cielo2, Riccardo Troncone2, Luigi Greco2.   

Abstract

BACKGROUND & AIMS: Potential celiac disease is characterized by positive results from serologic tests for tissue transglutaminase antibodies (anti-TG2) but normal duodenal architecture (Marsh stages 0-1). There is controversy over the best way to manage these patients. We investigated risk factors associated with the development of villous atrophy in children with potential celiac disease.
METHODS: We performed a prospective study of 280 children (ages 2-18 years) in Italy with suspected celiac disease, followed for up to 12 years (range, 18-150 months; median 60 months). The subjects had 2 consecutive positive results from tests for anti-TG2, tested positive for the endomysial antibody (anti-EMA), had total serum levels of immunoglobulin A in the normal range, normal duodenal architecture (Marsh stages 0-1) in 5 biopsies, and HLA DQ2- or DQ8-positive haplotypes. The children underwent serologic tests and clinical analyses every 6 months and a small bowel biopsy was taken every 2 years. A total of 210 patients of the original cohort were assessed at the 9-year follow-up evaluation. We performed multivariate analyses of clinical, genetic, and histologic data to identify factors associated with progression to villous atrophy.
RESULTS: During the follow-up period, 42 (15%) of 280 children developed villous atrophy, whereas 89 (32%) children no longer tested positive for anti-TG2 or anti-EMA. The cumulative incidence of progression to villous atrophy was 43% at 12 years. In multivariate analysis, the baseline factors most strongly associated with development of villous atrophy were numbers of γδ intraepithelial lymphocyte cells followed by age and homozygosity for the HLA DQB1*02. In discriminant analysis, these baseline factors identified 80% of the children who developed baseline atrophy.
CONCLUSIONS: In a long-term study of 280 children with suspected celiac disease (based on anti-TG2 and anti-EMA) on gluten-containing diets, the cumulative incidence of progression to villous atrophy was 43% over a 12-year period. We identified factors that can be used to identify children at highest risk for villous atrophy. This approach might be used to determine whether children with suspected celiac disease should immediately start a gluten-free diet or be monitored on their regular diet.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Food; Gluten-Free Diet; Treatment Selection

Mesh:

Substances:

Year:  2019        PMID: 30978358     DOI: 10.1053/j.gastro.2019.04.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  UEG Week 2020 Oral Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

Review 2.  Review on pediatric coeliac disease from a clinical perspective.

Authors:  Margreet Wessels; Renata Auricchio; Jernej Dolinsek; Ester Donat; Peter Gillett; Karl Mårild; Caroline Meijer; Alina Popp; M Luisa Mearin
Journal:  Eur J Pediatr       Date:  2022-01-15       Impact factor: 3.183

Review 3.  Review article: Becoming and being coeliac-special considerations for childhood, adolescence and beyond.

Authors:  Denis Chang; Delia O'Shea; Amelie Therrien; Jocelyn A Silvester
Journal:  Aliment Pharmacol Ther       Date:  2022-07       Impact factor: 9.524

Review 4.  Functional implications of the CpG island methylation in the pathogenesis of celiac disease.

Authors:  Souparni Ghosh; Preeti Khetarpal; Sabyasachi Senapati
Journal:  Mol Biol Rep       Date:  2022-05-28       Impact factor: 2.742

Review 5.  Can Celiac Disease Be Prevented?

Authors:  Renata Auricchio; Riccardo Troncone
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

6.  Five-year follow-up of new cases after a coeliac disease mass screening.

Authors:  Olof Sandström; Fredrik Norström; Annelie Carlsson; Lotta Högberg; Maria van der Palz; Lars Stenhammar; Charlotta Webb; Anneli Ivarsson; Anna Myléus
Journal:  Arch Dis Child       Date:  2021-12-17       Impact factor: 4.920

Review 7.  The Challenge of Treatment in Potential Celiac Disease.

Authors:  Chiara Maria Trovato; Monica Montuori; Francesco Valitutti; Beatrice Leter; Salvatore Cucchiara; Salvatore Oliva
Journal:  Gastroenterol Res Pract       Date:  2019-10-20       Impact factor: 2.260

8.  Transcriptional and Ultrastructural Analyses Suggest Novel Insights into Epithelial Barrier Impairment in Celiac Disease.

Authors:  Agnieszka Sowińska; Yasser Morsy; Elżbieta Czarnowska; Beata Oralewska; Ewa Konopka; Marek Woynarowski; Sylwia Szymańska; Maria Ejmont; Michael Scharl; Joanna B Bierła; Marcin Wawrzyniak; Bożena Cukrowska
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

Review 9.  Molecular Biomarkers for Celiac Disease: Past, Present and Future.

Authors:  Aarón D Ramírez-Sánchez; Ineke L Tan; B C Gonera-de Jong; Marijn C Visschedijk; Iris Jonkers; Sebo Withoff
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

10.  Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America.

Authors:  Kamran Badizadegan; David M Vanlandingham; Wesley Hampton; Kimberly M Thompson
Journal:  BMC Health Serv Res       Date:  2020-10-20       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.